Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829606 | PMC |
| http://dx.doi.org/10.1016/j.jds.2023.08.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic significance and therapeutic potential of guanosine triphosphate cyclohydrolase 1 in esophageal squamous cell carcinoma: clinical implications of ferroptosis and lipid peroxidation regulation.
Front Oncol
December 2024
Department of Human Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Background: Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is a leading cause of cancer-related death and has a poor prognosis. Despite the advancements in multidisciplinary therapies, resistance to conventional treatments warrants the development of novel therapeutic strategies. Ferroptosis, a form of cell death dependent on intracellular iron, has emerged as a potential mechanism for targeting cancer cells resistant to apoptosis.
View Article and Find Full Text PDFCase report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.
Front Pharmacol
December 2024
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Article Synopsis
- Driver mutations in tyrosine kinases like ALK are important in non-small cell lung cancer but uncommon in large cell neuroendocrine carcinoma (LCNEC).
- A 55-year-old woman with a history of breast cancer developed advanced LCNEC 10 years later, exhibiting multiple brain metastases and testing positive for the ALK fusion gene, leading to treatment with lorlatinib.
- The patient showed a significant tumor reduction after 6 weeks of lorlatinib therapy, indicating that ALK-positive advanced LCNEC might respond well to this treatment, especially for brain metastases.
[A Case of Hepatocellular Carcinoma with Simultaneous Bone Metastasis Successfully Treated with Multidisciplinary Therapy].
Gan To Kagaku Ryoho
December 2024
Dept. of Digestive Surgery, Tenri Hospital.
The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively.
View Article and Find Full Text PDFAssembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis.
Acta Biomater
December 2024
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, China. Electronic address:
Osteosarcoma tissues demonstrated elevated expression of proteins (FDX1 and DLAT) integral to cuproptosis in our preliminary study, indicating the potential effectiveness of anti-tumor strategies predicated on this process. Nevertheless, the overexpression of copper export proteins and the challenge of copper ion penetration may contribute to insufficient local copper ion concentration for inducing cuproptosis. Herein, we engineered a biomimetic copper-elesclomol-polyphenol network for the efficient delivery of copper ions and the copper ionophore elesclomol.
View Article and Find Full Text PDFTGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosis.
Cell Death Dis
December 2024
University of Zürich, Institute of Anatomy, Winterthurerstrasse 190, 8057, Zürich, Switzerland.
The TGFβ signaling pathway is known for its pleiotropic functions in a plethora of biological processes. In melanoma, TGFβ signaling promotes invasiveness and metastasis formation. However, its involvement in the response to therapy is controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!